TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 23.57.
| Share Price | ₹298.7 | Jan 23,2026 |
| Market Cap | ₹355.4 Cr | |
| Earnings-TTM | ₹15.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 23.57x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹355.4 Cr] as on Jan 23,2026
(/) Earnings [ ₹15.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 23.57x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 23.57 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2025 to Mar2022 averaged 21.32x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 4 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| TRIDENT LIFELINE | 15.08 | 23.57 | 355.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 37.22 | 391,488.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 64.15 | 159,415.0 |
| CIPLA LTD | 4,544.70 | 23.37 | 106,210.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 62.11 | 132,906.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.71 | 103,089.0 |
| MANKIND PHARMA LTD | 1,767.06 | 49.12 | 86,802.6 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 17.84 | 88,744.8 |
| LUPIN LTD | 4,347.53 | 22.46 | 97,624.8 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.09 | 65,813.5 |
| ABBOTT INDIA LTD | 1,508.95 | 39.19 | 59,136.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.84x |
| Max industry PE | 64.15x |
| Median industry PE | 23.57x |
| Average industry PE | 34.26x |
You may also like the below Video Courses